CONNECT WITH US
HealthTech

HealthTech

A single CRISPR infusion lowers blood fats in monkeys for three years

Medical Xpress logo

Published on

Add as a preferred source on Google
A single CRISPR infusion lowers blood fats in monkeys for three years

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

High levels of LDL cholesterol and triglycerides, which are types of blood fats, are major contributors to atherosclerotic cardiovascular disease. Gene-editing technologies offer a potential alternative to lipid-lowering medications. In a new CRISPR experiment, a single infusion of a gene-editing treatment kept triglyceride levels low in monkeys for three years. The findings support the possibility of controlling blood fats with a lasting DNA change, potentially replacing daily doses of medication.

Researchers at Verve Therapeutics and collaborating institutions report the results in Nature. Verve, an Eli Lilly subsidiary, funded the work. Most authors are company employees, and several hold Lilly shares or are named on related patent applications.

The treatment disables ANGPTL3, a gene encoding a liver-secreted protein that slows the clearance of fats from the blood. Reducing that protein can lower both triglycerides and LDL cholesterol.

The gene has already been identified as a treatment target: evinacumab, an antibody drug for a severe inherited cholesterol disorder, blocks ANGPTL3 but administration requires infusions every four weeks. Gene editing aims instead to stop the liver from producing the protein.

To build their single-course treatment, the researchers packaged RNA instructions for a CRISPR base editor and an RNA guide inside tiny fat-based particles. The guide directs the editor to ANGPTL3, where changing one DNA letter disrupts the instructions for making the protein. The delivery components and RNA are largely cleared after treatment, and the DNA change is designed to remain.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.